⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2024

Supplementary Figure 1 from The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles

Haley D. Neff‐LaFord Sarah A. Carratt Christopher M. Carosino Nancy Everds Kristen A. Cardinal Steven Duniho Melissa M. Schutten Christopher Frantz Christina L. Zuch de Zafra Eric B. Harstad

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 1. Hematopoietic and lymphoid tissue toxicity in cynomolgus monkeys administered a vedotin ADC or MMAE.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Neff‐LaFord et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efef94 https://doi.org/10.1158/1535-7163.27142297

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles2024
2Data from The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles2024
3The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles2024 · 28 citations
4Supplementary Figure S4 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates2024
5Supplementary Figure S4 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates2024

More related papers

Supplementary Figure 8 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs2025
Supplementary Fig.S13 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024
Supplementary Fig.S13 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers2024